A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN ASIAN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS

placebo

CP-690,550

CP-690,550

Percentage of Participants With Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" at Week 16

Percentage of Participants Achieving at Least a 75% Reduction in PASI (PASI75) at Week 16

Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16

Percentage of Participants Achieving at Least a 90% Reduction in PASI (PASI90) at Week 16

Change From Baseline in DLQI Total Score at Week 16

Percentage of Participants With PGA Score of "Clear" or "Almost Clear" at Week 4

Percentage of Participants Achieving PASI75 Response at Week 4

Change From Baseline in DLQI Total Score at Week 4

Percent Change From Baseline in Nail Psorasis Severity Index (NAPSI) at Week 16 in Participants With Nail Psoriasis at Baseline

Percentage of Participants Maintaining PGA Score of "Clear" or "Almost Clear" at Week 52 Among Participants Achieving PGA Response at Week 16

Percentage of Participants Maintaining PASI75 Response at Week 52 Among Participants Achieving PASI75 Response at Week 16

Percentage of Participants Maintaining PASI90 Response at Week 52 Among Participants Achieving PASI90 at Week 16

Time to PGA Response up to Week 16

Time to PASI75 Response up to Week 16

Time to PASI50 Response up to Week 16

Percentage of Participants With PGA Response of 'Clear' or 'Almost Clear' Over Time Through Week 52

Percentage of Participants in Each PGA Category Over Time Through Week 52

Percentage of Participants Achieving PASI75 Response Over Time Through Week 52

Actual PASI Scores Over Time Through Week 52

Change From Baseline in PASI Over Time Through Week 52

PASI Component Scores Over Time Through Week 52

Change From Baseline in PASI Component Scores Over Time Through Week 52

Percent Change From Baseline in PASI Scores Over Time Through Week 52

Actual BSA Over Time Through Week 52

Percent Change From Baseline in BSA Over Time Through Week 52

Percentage of Participants With PASI50 Response Over Time Through Week 52

Percentage of Participants With PASI90 Response Over Time Through Week 52

Percentage of Participants With PASI125 Over Time Through Week 52

Actual Nail Psoriasis Severity Index (NAPSI) Score Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline

Change From Baseline in NAPSI Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline

Number of Affected Nails in Participants With Nail Psoriasis at Baseline Over Time Through Week 52

Percent Change From Baseline in NAPSI Over Time Through Week 52

Percentage of Participants With NAPSI75 Response Over Time Through Week 52

Percentage of Participants With NAPSI100 Response Over Time Through Week 52

Actual Itch Severity Item (ISI) Score Over Time Through Week 52

Change From Baseline in ISI Score Over Time Through Week 52

Actual Dermatology Life Quality Index (DLQI) Score Over Time Through Week 52

Change From Baseline in DLQI Score Over Time Through Week 52

Percentage of Participants With Patient Global Assessment (PtGA) Response of "Clear" or "Almost Clear" Over Time Through Week 52

Euro Quality of Life 5 Dimensions (EQ-5D) - Utility Score Over Time Through Week 52

Change From Baseline in EQ-5D - Utility Score Over Time Through Week 52

Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) Over Time Through Week 52

Change From Baseline in EQ-5D - Visual Analog Scale (VAS) Over Time Through Week 52